Expression and a role of CD30 in regulation of T-cell activity

Current Opinion in Hematology

Volumn 10, Issue 4, 2003, Pages 267-271

  Tarkowski, Maciej ^a  

^a NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 RECEPTOR; CYTOKINE; IMMUNOTOXIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

BINDING SITE; CELL ACTIVITY; CELL DEATH; CELL STIMULATION; CLINICAL TRIAL; CROSS LINKING; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MARKER; DRUG TARGETING; HODGKIN DISEASE; HUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH2 CELL;

ANTIGENS, CD30; ANTIGENS, NEOPLASM; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0038308345     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200307000-00003     Document Type: Review

References (72)

1. Schwab U, Stein H, Gerdes J, et al.: Production of monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982, 299:65-67.
2. Durkop H, Latza U, Hummel U, et al.: Molecular cloning and expression of a new member of the growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992, 68:421-427.
3. Gruss H-J, Dower SK: Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995, 85:3378-3404.
4. Aizawa S, Nakano H, Ishida T, et al.: Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem 1997, 272:2042-2045.
5. Duckett CS, Gedrich RW, Gilfillan MC, et al.: Induction of nuclear factor kB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cel Biol 1997, 17:1535-1542.
6. Stein H, Mason DY, Gerdes J, et al.: The expression of Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985, 66:848-858.
7. Ellis TM, Simms PE, Slivnick DJ, et al.: CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol 1993, 151:2380-2389.
8. Aggraval B, Reddish M, Longenecker B: CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes from normal donors. J Immunol 1996, 157:3229-3234.
9. Sun Y, Song M, Maeurer MJ, et al.: Segregation of effector mechanisms in a tumor-specific CD8+ T-cell clone correlates with CD30 expression. Scand J Immunol 2001, 54:314-320.
10. Stanciu LA, Roberts K, Lau LCK, et al.: Induction of type 2 activity in adult human CD8+ T cells by repeated stimulation and IL-4. Int Immunol 2001, 13:341-348.
11. Biswas P, Rovere P, Filippi CD, et al.: Engagement of CD30 shapes the secretion of cytokines by human gamma delta T cells. Eur J Immunol 2000, 30:2172-2180.
12. Dagna L, lellem A, Biswas P, et al.: Skewing of cytotoxic activity and chemokine production, but not of chemokine receptor expression, in human type-1/-2 gamma delta T lymphocytes. Eur J Immunol 2002, 32:2934-2943.
13. Falini B, Pileri S, Pizzolo G, et al.: CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995, 85:1-14.
14. Shanebeck K, Maliszewski C, Kennedy M, et al.: Regulation of murine B cell growth and differentiation by CD30 ligand. Eur J Immunol 1995, 25:2147-2153.
15. Cambiaggi A, Cantoni C, Marciano S, et al.: Cultured human NK cells express the Ki-1/CD30 antigen. Br J Haematol 1993, 85:270-276.
16. Durkop H, Foss H-D, Eitelbach F, et al.: Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol 2000, 190:613-618.
17. Alzona M, Jack H-M, Fisher RI, et al.: CD30 defines a subset of activated human T cells that produce IFN-g and IL-5 and exhibit enhanced B cell helper activity. J Immunol 1994, 153:2861-2867.
18. Chan KW, Hopke CD, Krams SM, et al.: CD30 expression identifies the predominant proliferating T lymphocyte population in human alloimmune responses. J Immunol 2002, 169:1784-1791. A nice study showing the importance of CD30 T cells in the context of transplantation.
19. Del Prete G, De Carli M, Almerigogna F, et al.: Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J 1995, 9:81-86.
20. Leonard C, Tormey V, Burke C, et al.: Allergen-induced cytokine production in atopic diseases and its relationship to disease severity. Am J Respir Cell Mol Biol 1997, 17:368-375.
21. Nakamura T, Lee RK, Nam SY, et al.: Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-g. J Immunol 1997, 158:2090-2096.
22. Tarkowski M, Chrul S, Bodalski J: The effect of IL-18 on IL-12 induced CD30 expression and IL-4 and IFN-g production by allergen and PPD specific T cells. Clin Exp Immunol 2002, 127:78-84.
23. Rossi FM, Degan M, Mazzocut-Zecchin L, et al.: CD30L up-regulates CD30 and IL-4 expression by T cells. FEBS Lett 2001, 508:418-422.
24. Gilfillan MC, Noel PJ, Podack ER, et al.: Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol 1998, 160:2180-2187.
25. Vermeer MH, Cornelis TP, van der Stoop PM, et al.: Absence of Th2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas. Arch Dermatol 2001, 137:901-905.
26. Romagnani S, Del Prete G, Maggi E, et al.: CD30 and type 2 T helper (Th2) responses. J Leukoc Biol 1995, 57:726-730.
27. Frezzolini A, Paradisi M, Ruffelli M, et al.: Soluble CD30 in pediatric patients with atopic dermatitis. Allergy 1997, 52:106-109.
28. Folster-Holst R, Henseler T, Wehde J, et al.: Soluble CD30 plasma concentrations correlate with diseases activity in patients with atopic dermatitis. Acta Derm Venereol 2002, 82:245-248.
29. D'Elios MM, Romagnani P, Scaletti C, et al.: In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. J Leukoc Biol 1997, 61:539-544.
30. Spinozzi F, Agea E, Piattoni S, et al.: Lack of correlation between membrane CD30 expression and cytokine secretion pattern in allergen-primed naive cord blood T-cell lines and clones. Scand J Immunol 1997, 45:417-422.
31. Munk ME, Kern P, Kaufmann SHE: Human CD30+ cells are induced by Mycobacterium tuberculosis and present in tuberculosis lesions. Int Immunol 1997, 9:713-720.
32. Bengtsson A, Johansson C, Tengvall Linder M, et al.: Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation. J Leukocyte Biol 1995, 58:683-689.
33. Alzona M, Jack H-M, Fisher RI, et al.: IL-12 activates IFN-g production through the preferential activation of CD30+ T cells. J Immunol 1995, 154:9-16.
34. Sun Y, Song M, Maeurer MJ, et al.: Segregation of effector mechanisms in a tumor-specific CD8+ T cell clone correlates with CD30 expression. Scand J Immunol 2001, 54:314-320.
35. Bengtsson A: The role of CD30 in atopic disease. Allergy 2001, 56:593-603.
36. Schade RP, Van leperen-Van Dijk AG, Versluis C, et al.: Cell-surface expression of CD25, CD26, and CD30 by allergen-specific T cells is intrinsically different in cow's milk allergy. J Allergy Clin Immunol 2002, 109:357-362.
37. Kleinhans M, Tun-Kyi A, Gilliet M, et al.: Functional expression of the eotaxin receptor CCR3 in CD30 positive cutaneous T cell lymphoma. Blood 2003, 101:1487-1493. An important study bringing closer the connection between site-specific recruitment of lymphoma cells and their functional state.
38. Vinante F, Rigo A, Scupoli MT, et al.: CD30 triggering by agonistic antibodies regulates CXCR4 expression and CXCL12 chemotactic activity in the cell line L540. Blood 2002, 99:52-60. Another important study adding information on the possibility of cancer cell dissemination through upregulation of chemokine receptor expression.
39. Vermeer MH, Dukers DF, ten Berge RL, et al.: Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease. Mod Pathol 2002, 15:838-844. An important study analyzing the coexpression of TARC chemokine and CCR4 as a suggested mechanism of cancer cell dissemination.
40. Adachi Y, Onoue Y, Yamamoto J, et al.: Selective expression of CD30 and CCR4, but not CCR3, on circulating CD4+ cells as a marker for Th2-type. J Allergy Clin Immunol 2000, 105:S154.
41. Gerli R, Pitzalis C, Bistoni O, et al.: CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J Immunol 2000, 164:4399-4407.
42. Del Prete G, De Carli M, D'Elios MM, et al.: CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J Exp Med 1995, 182:1655-1661.
43. Nam S-Y, Che K-S, Hee Y-M, et al.: Regulation of lymphocyte clustering by CD30-mediated ICAM-1 up-regulation. Cell Immunol 2002, 219:38-47.
44. Gruss HJ, Ulrich D, Dower SK, et al.: Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-kappa beta transcription factor. Blood 1996, 87:2443-2449.
45. Deleted in proofs.
46. Harlin H, Podack E, Boothby M, et al.: TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism. J Immunol 2002, 169:2451-2460. An excellent study showing the TCR-independent effect of CD30 stimulation on cytokine production. The article also brings closer involvement of intracellular signaling mediators.
47. Lee SY, Park CG, Choi Y: T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med 1996, 183:669-674.
48. Powell IF, Li T, Jack HM, et al.: Construction and expression of a soluble form of human CD30 ligand with functional activity. J Leukoc Biol 1998, 63:752-757.
49. Hubinger G, Muller E, Scheffrahn I, et al.: CD30-mediated cell cycle arrest associated with induced expression of p21 (CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. Oncogene 2001, 20:590-598.
50. Hargreaves PG, Al-Shamkhani A: Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur J Immunol 2002, 32:163-173.
51. Gruss HJ, Boiani N, Williams DE, et al.: Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994, 83:2045-2051.
52. Maggi E, Annunziato F, Manetti R, et al.: Activation of HIV expression by CD30 triggering in CD4+ cells from HIV-infected individuals. Immunity 1995, 3:251-255.
53. Gruss HJ, Boiani N, Williams DE, et al.: Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994, 83:2045-2056.
54. Schneider C, Hubinger G: Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family. Leuk Lymphoma 2002, 43:1355-1366.
55. Beucher L-M, Marengere LEM, Lu Y, et al.: Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. Biochem Biophys Res Commun 1997, 233:592-600.
56. Gedrich RW, Gilfillan MC, Duckett CS, et al.: CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem 1996, 271:12852-12858.
57. Horie R, Watanabe T, Morishita Y, et al.: Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 2002, 21:2493-2503. This excellent article implicates CD30 in the process of constitutive cytokine expression, implicates NFκB in CD30-induced interleukin-13 production, and provides molecular bases of cancer.
58. Horie R, Watanabe T, Ite K, et al.: Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells. Am J Pathol 2002, 160:1647-1654. An important study characterizing molecular bases for CD30 overexpression related NFκB stimulation.
59. Ansieau S, Scheffrahn I, Mosialos G, et al.: Tumor necrosis factor receptor associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc Natl Acad Sci U S A 1996, 93:14053-14058.
60. Duckett CS, Gedrich RW, Gilfillan MC, et al.: Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cel Biol 1997, 17:1535-1542.
61. Aizawa S, Nakano H, Ishida T, et al.: Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem 1997, 272:2042-2045.
62. Blackwell TS, Christman JW: The role of nuclear factor-kappa B in cytekine gene regulation. Am J Respir Cell Mol Biol 1997, 17:3-9.
63. Gruss HJ, Ulrich D, Dower SK, et al.: Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-kappa beta transcription factor. Blood 1996, 87:2443-2449.
64. Duckett CS, Thompson CB: CD30-mediated degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev 1997, 11:2810-2821.
65. Gerli R, Lunardi C, Vinante F, et al.: Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol 2001, 22:72-77.
66. Hansen HP, Matthey B, Barth S, et al.: Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin. Int J Cancer 2002, 98:210-215. An important study adding information on CD30 receptor expression stability and the possibility of overcoming its shedding from the cell sudace, implicating important practical issues for further therapies.
67. Leonard C, Tormey V, Faul J, et al.: Allergen-induced CD30 expression on T cells of atopic asthmatics. Clin Exp Allergy 1997, 27:780-786.
68. Kurts C, Carbone FR, Krummel MF, et al.: Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 1999, 398:341-344.
69. Roy R, Dugre F, Berube L, et al.: CD30 and TNF-alpha serum level as indicators of ongoing acute kidney graft rejection. Hum Immunol 2002, 63:S75.
70. Zanotti R, Trolese A, Ambrosetti A, et al.: Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Ann Oncol 2002, 12:1908-1914.
71. Huhn M, Sasse S, Tur MK, et al.: Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 2001, 61:8737-8742.
72. Schnell R, Staak O, Borchmann P, et al.: A phase I study with an anti-CD30 ricin a-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 2002, 8:1779-1786.